Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional) | RFA DK 18 002

Opportunity Information: Apply for RFA DK 18 002

The grant opportunity titled "Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional)" (Funding Opportunity Number RFA-DK-18-002) is a National Institutes of Health (NIH) discretionary research grant that supports studies aimed at clarifying how type 1 diabetes (T1D) influences skeletal health. The central focus is on understanding the effects of T1D on bone mass and bone quality and how these changes may translate into altered fracture risk. In practical terms, the FOA is looking for well-justified research projects that can explain why people with T1D may experience differences in bone strength, structure, or fracture incidence, and what biological or clinical factors drive those outcomes.

The announcement is structured around the NIH R01 mechanism, which typically funds substantial, hypothesis-driven projects with clear aims, rigorous methods, and strong investigative teams. The "Clinical Trial Optional" designation means applicants can propose either clinical trial work or non-trial human studies, depending on what best fits the scientific question. Projects may involve newly recruited participants with T1D, which would allow investigators to design tailored protocols for bone imaging, biomarker collection, clinical phenotyping, and longitudinal follow-up. Alternatively, applicants may leverage existing cohorts, ongoing clinical studies, or stored biospecimens from prior or current T1D research, which can be a powerful and efficient way to address skeletal questions while building on already-characterized populations.

From an applicant standpoint, the opportunity is broadly open to many organization types, reflecting NIH's standard approach to encouraging diverse institutional participation. Eligible applicants include state, county, city/township, and special district governments, as well as independent school districts. A wide range of higher education institutions can apply, including public/state-controlled and private institutions. The FOA also accepts applications from federally recognized Native American tribal governments, tribal organizations that are not federally recognized, and public housing authorities/Indian housing authorities. Both nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities) and for-profit organizations (other than small businesses), as well as small businesses, are listed as eligible. In addition, the FOA explicitly calls out several other eligible applicant categories to broaden participation, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, Indian/Native American tribal governments that are not federally recognized, and even non-U.S. (foreign) entities.

Administrative details in the source information indicate the responsible agency is NIH, with the program associated with CFDA number 93.847 and an activity category spanning food and nutrition and health. The original closing date listed is December 6, 2018, and the entry shows a creation date of May 8, 2018. The award ceiling is stated as $400,000, indicating the maximum funding level referenced in the opportunity materials (commonly interpreted as a cap tied to budget parameters in that FOA). The "ExpectedAwards" field is present but not populated in the provided data, so the number of anticipated awards cannot be inferred from the excerpt.

Overall, this FOA is geared toward advancing a more precise understanding of diabetic bone disease in type 1 diabetes by supporting studies that connect clinical characteristics of T1D to measurable changes in skeletal outcomes such as bone density, bone microarchitecture or material properties, and fractures. It encourages designs that can use either fresh recruitment or well-curated existing clinical resources, and it is open to a wide range of domestic and international institutions and organizations capable of executing high-quality research in this area.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Understanding Skeletal Effects of Type 1 Diabetes (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2018-05-08.
• Applicants must submit their applications by 2018-12-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $400,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 18 002

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: